mCRPC in focus
Transcript: Treatment strategies that can address unmet needs for mCRPC
Professor Axel Merseburger
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
So, definitely in mCRPC, there are unmet needs that sometimes negatively affect the outcomes of our men with this deadly disease. So, the question, "What are the unmet needs that negatively affect the mCRPC outcomes?"
So first, and this is not always advised to discuss with your patients, but we all know this. In mCRPC, we don't have a curative treatment as of yet, so it's a palliative disease setting. Also, questions derive, "What is the optimal treatment selection", since there are very few head-to-head trials comparing the drugs and treatments we have. This leads into the often unanswered question, "What is the optimal sequencing, and what is the best treatment approach?" Is it monotherapy?
Is it intensification? Is it some triplet approach of the treatments? This has to be weighted with the possible adverse events management, and also disease monitoring. And also something to discuss, we have the PSA, the prostate cancer antigen biomarker, which leads us, but we also need to look at the clinic of the patient, and also need at the imaging and regular follow ups in order to see in which direction the disease is developing. So, we have strategies that could help to overcome those unmet needs in mCRPC. So new one is, for example, new first line treatments for mCRPC, which are on the horizon.
Also, monotherapies and combination therapies, which might make the treatment of mCRPC not only easier, but also on the other hand, more efficacious. And hopefully, also, with less side effects for our men we treat with metastatic castration-resistant prostate cancer.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.